Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Oncolytic viruses get a boost with first FDA-approval recommendation

An Erratum to this article was published on 16 June 2015

This article has been updated

The future of cancer-killing viruses lies in their potential to augment cell and antibody immunotherapies.

This is a preview of subscription content, access via your institution

Access options

Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Change history

  • 16 June 2015

    In Table 1 of this article, the name of the oncolytic virus being developed by DNAtrix should have read 'DNX-2401'. This has been corrected in the online version of the article.


PowerPoint slides

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Dolgin, E. Oncolytic viruses get a boost with first FDA-approval recommendation. Nat Rev Drug Discov 14, 369–371 (2015).

Download citation

  • Published:

  • Issue Date:

  • DOI:

This article is cited by


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing